Cytokinetics Q1 2024 Earnings Report
Key Takeaways
Cytokinetics reported a net loss of $135.6 million for the first quarter of 2024, compared to a net loss of $131.3 million for the same period in 2023. The company's cash, cash equivalents, and investments totaled $634.3 million as of March 31, 2024. Key activities included advancing the aficamten development program, initiating enrollment in the CEDAR-HCM trial, and progressing CK-586 towards a Phase 2 clinical trial.
Advanced aficamten development program with multiple clinical trials ongoing.
Initiated enrollment in CEDAR-HCM, a clinical trial of aficamten in a pediatric population.
Progressed CK-586 towards a Phase 2 clinical trial expected to begin in Q4 2024.
Participated in meetings with the FDA regarding the New Drug Application (NDA) for aficamten, planned for submission in Q3 2024.